S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Why Lucid Spiked Nearly 100% In One Day
Is This The End of Capitalism? (Ad)
Is Buying an Aged Corporation a Good Idea?
MarketBeat Week in Review – 1/23- 1/27
Is This The End of Capitalism? (Ad)
Visa, L3Harris rise; Intel, Eastman Chemical fall
How major US stock indexes fared Friday 1/27/2023
The Next Big Crisis Is Here (Ad)
Closing prices for crude oil, gold and other commodities
House GOP seeks new restrictions on use of US oil stockpile
NASDAQ:NKTR

Nektar Therapeutics - NKTR Stock Forecast, Price & News

$2.61
+0.15 (+6.10%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.41
$2.63
50-Day Range
$2.03
$3.43
52-Week Range
$1.99
$11.59
Volume
1.79 million shs
Average Volume
1.14 million shs
Market Capitalization
$490.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40

Nektar Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
1.92 Rating Score
Upside/​Downside
221.8% Upside
$8.40 Price Target
Short Interest
Bearish
4.91% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
1.47mentions of Nektar Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$223,371 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.14) to ($1.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

363rd out of 1,055 stocks

Pharmaceutical Preparations Industry

166th out of 519 stocks


NKTR stock logo

About Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Nektar Therapeutics: Recovery Seems To Be A Mirage
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates
Nektar Therapeutics Q3 Loss decreases, beats estimates
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
PureTech Health and Nektar Therapeutics end tie-up talks
Nektar Therapeutics, PureTech End Merger Talks - Quick Facts
Nektar Therapeutics (NKTR)
Nektar Therapeutics Presents Data for...
See More Headlines
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Company Calendar

Last Earnings
11/03/2022
Today
1/28/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:NKTR
CUSIP
64026810
Employees
740
Year Founded
1990

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+221.8%
Consensus Rating
Hold
Rating Score (0-4)
1.92
Research Coverage
12 Analysts

Profitability

Net Income
$-523,840,000.00
Net Margins
-477.85%
Pretax Margin
-477.78%

Debt

Sales & Book Value

Annual Sales
$101.91 million
Book Value
$3.68 per share

Miscellaneous

Free Float
181,601,000
Market Cap
$490.55 million
Optionable
Optionable
Beta
1.04

Social Links


Key Executives

  • Howard W. RobinHoward W. Robin
    President, Chief Executive Officer & Director
  • Jillian B. ThomsenJillian B. Thomsen
    Chief Financial Officer & Senior Vice President
  • Jonathan ZalevskyJonathan Zalevsky
    Chief Research & Development Officer
  • Brian L. Kotzin
    Chief Medical Officer & Senior Vice President
  • Mary Tagliaferri
    Senior Vice President













NKTR Stock - Frequently Asked Questions

Should I buy or sell Nektar Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings
or view top-rated stocks.

What is Nektar Therapeutics' stock price forecast for 2023?

12 Wall Street analysts have issued 12 month price objectives for Nektar Therapeutics' shares. Their NKTR share price forecasts range from $3.00 to $21.00. On average, they anticipate the company's stock price to reach $8.40 in the next twelve months. This suggests a possible upside of 221.8% from the stock's current price.
View analysts price targets for NKTR
or view top-rated stocks among Wall Street analysts.

How have NKTR shares performed in 2023?

Nektar Therapeutics' stock was trading at $2.26 at the beginning of the year. Since then, NKTR shares have increased by 15.5% and is now trading at $2.61.
View the best growth stocks for 2023 here
.

When is Nektar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our NKTR earnings forecast
.

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings data on Thursday, November, 3rd. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.23. The biopharmaceutical company had revenue of $23.63 million for the quarter, compared to analysts' expectations of $23.31 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 81.70% and a negative net margin of 477.85%.

What is Howard W. Robin's approval rating as Nektar Therapeutics' CEO?

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Nektar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.10%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%), Inspire Investing LLC (0.06%), Hennion & Walsh Asset Management Inc. (0.05%) and Maryland State Retirement & Pension System (0.04%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends
.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $2.61.

How much money does Nektar Therapeutics make?

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $490.55 million and generates $101.91 million in revenue each year. The biopharmaceutical company earns $-523,840,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis.

How many employees does Nektar Therapeutics have?

The company employs 740 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.

This page (NASDAQ:NKTR) was last updated on 1/28/2023 by MarketBeat.com Staff